Spojené státy - angličtina - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

Spojené státy - angličtina - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

Spojené státy - angličtina - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

Spojené státy - angličtina - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

Kanada - angličtina - Health Canada

eli lilly canada inc - atomoxetine (atomoxetine hydrochloride) - capsule - 25mg - atomoxetine (atomoxetine hydrochloride) 25mg - miscellaneous central nervous system agents

Tunisko - francouzština - Ministère de la Santé, Direction de l'inspection Pharmaceutique

lilly s.a espagne - atomoxetine - gélule - 25 mg - systeme nerveux - psychoanaleptiques - strattera est indiqué dans le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah) chez les enfants de 6 ans et plus et chez les adolescents dans le cadre d'une prise en charge thérapeutique globale. le traitement doit être initié par un spécialiste dans le traitement du tdah comme un pédiatre, un pédopsychiatre ou un psychiatre. le diagnostic doit être établi selon les critères actuels du dsm ou de l'icd.

Litva - litevština - SMCA (Valstybinė vaistų kontrolės tarnyba)

eli lilly nederland b.v. - atomoksetinas - kietosios kapsulės - 40 mg; 25 mg; 18 mg; 10 mg; 60 mg - atomoxetine

Slovensko - slovenština - ŠÚKL (Štátny ústav pre kontrolu liečiv)

eli lilly Čr, s.r.o., Česká republika - atomoxetín - 78 - sympathomimetica

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

eli lilly Čr, s.r.o., praha array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 10mg - atomoxetin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

eli lilly Čr, s.r.o., praha array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 100mg - atomoxetin